Ventria Bioscience’s InVitria Division Awarded 2-Year, $1.5 Million Grant to Develop Superior System for Cell-Based Vaccine Production
Published: Jun 04, 2012
FORT COLLINS, Colo.--(BUSINESS WIRE)--Ventria Bioscience today announced that its non-therapeutic products division InVitria has been awarded a new Small Business Innovation Research Program (SBIR) grant from the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID). The funds total $1.5 million over 2 years, and will support a collaborative research and development effort between InVitria; The Institute for Antiviral Research at Utah State University (Logan, Utah); SoloHill Engineering, Inc. (Ann Arbor, Mich.); and the U.S. Centers for Disease Control and Prevention’s Division of Vector-Borne Diseases (Fort Collins, Colo.). The focus of the research is to use InVitria’s cell culture supplements to develop a novel, animal-free, defined cell culture media for the commercial production of cell-based vaccines.